<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedBookArticle><BookDocument><PMID Version="1">30085580</PMID><ArticleIdList><ArticleId IdType="bookaccession">NBK519038</ArticleId></ArticleIdList><Book><Publisher><PublisherName>StatPearls Publishing</PublisherName><PublisherLocation>Treasure Island (FL)</PublisherLocation></Publisher><BookTitle book="statpearls">StatPearls</BookTitle><PubDate><Year>2022</Year><Month>01</Month></PubDate><BeginningDate><Year>2022</Year><Month>01</Month></BeginningDate><Medium>Internet</Medium></Book><ArticleTitle book="statpearls" part="article-26659">Parathyroid Cancer</ArticleTitle><Language>eng</Language><AuthorList Type="authors" CompleteYN="Y"><Author ValidYN="Y"><LastName>Byrd</LastName><ForeName>Colin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>McLaren Oakland</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kashyap</LastName><ForeName>Sarang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Easton Hospital</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwartowitz</LastName><ForeName>Gary</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>McLaren Oakland</Affiliation></AffiliationInfo></Author></AuthorList><PublicationType UI="D000072643">Study Guide</PublicationType><Abstract><AbstractText>Parathyroid carcinoma is a rare, malignant neoplasm originating from the parathyroid gland. The normal weight and size of the parathyroid glands vary. The average weight is about 60 mg. The average dimensions of each gland are 5 mm in length by 3 mm in width and 1 mm in thickness. The color of normal parathyroid glands is a yellow-brown color. There are generally 4 parathyroid glands, 2 superior and 2 inferior glands; they are located on the posterior and lateral surface of the thyroid gland. The location of the glands may vary based on the embryological descent during development. The inferior parathyroids and the thymus both develop from the third branchial pouch, whereas the parafollicular C cells and the superior parathyroids develop from the fourth branchial pouch. The superior parathyroid glands are frequently found near the cricothyroid junction, just superior to the intersection of the recurrent laryngeal nerve and the inferior thyroid artery. The superior parathyroids are closely associated with the posterior capsule of the superior thyroid pole. The inferior parathyroids have a more variable location, and greater than 50% are located at the inferior thyroid pole, but they can be located in the anterior mediastinum along the thyrothymic ligament. Rarely there is the presence of a supernumerary gland. The association of the parathyroid glands to the recurrent laryngeal nerve is an important anatomical relationship. The superior parathyroids are deep to the recurrent laryngeal nerve, and the inferior parathyroids are superficial. In most cases, each parathyroid gland's arterial supply is derived from the inferior thyroid artery, which is a branch of the thyrocervical trunk.  In 20% of cases, it may derive its blood supply from the superior thyroid artery, which is a branch from the external carotid artery. There is generally rich anastomosis between the parathyroids, larynx, pharynx, esophagus, and trachea. The venous drainage parallels the arterial vessels and drains into the internal jugular. The lymphatics of the parathyroid drain into the deep cervical and pretracheal lymph nodes, similar to the lymphatic drainage of the thyroid gland.  The major functional cells of the parathyroid are the chief cells, which contain many cytoplasmic secretory granules. These are responsible for producing parathyroid hormone. The second cell type that makes up the parathyroid parenchyma is the oxyphil cell. Their function is unknown, but they tend to be rich in mitochondria. Parathyroid glands with high concentrations of oxyphil cells may be more prone to hyperfunction.  As with all malignancy, parathyroid carcinoma is a result of the uncontrolled or unregulated growth of the parathyroid cells, and most parathyroid carcinomas are functional - meaning they secrete parathyroid hormone (PTH). Parathyroid carcinoma can occur in any of the parathyroids and does not appear to have a predilection for either the superior or inferior glands (or supernumerary glands), though the rarity of the disease precludes any definitive conclusions. The hallmark characteristic is a very high serum PTH level, often into the thousands, which is rare in benign hyperparathyroidism.</AbstractText><CopyrightInformation>Copyright © 2022, StatPearls Publishing LLC.</CopyrightInformation></Abstract><Sections><Section><SectionTitle book="statpearls" part="article-26659" sec="article-26659.s1">Continuing Education Activity</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26659" sec="article-26659.s2">Introduction</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26659" sec="article-26659.s3">Etiology</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26659" sec="article-26659.s4">Epidemiology</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26659" sec="article-26659.s5">Pathophysiology</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26659" sec="article-26659.s6">Histopathology</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26659" sec="article-26659.s7">History and Physical</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26659" sec="article-26659.s8">Evaluation</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26659" sec="article-26659.s9">Treatment / Management</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26659" sec="article-26659.s10">Differential Diagnosis</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26659" sec="article-26659.s11">Staging</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26659" sec="article-26659.s12">Prognosis</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26659" sec="article-26659.s13">Postoperative and Rehabilitation Care</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26659" sec="article-26659.s14">Consultations</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26659" sec="article-26659.s15">Deterrence and Patient Education</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26659" sec="article-26659.s16">Pearls and Other Issues</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26659" sec="article-26659.s17">Enhancing Healthcare Team Outcomes</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26659" sec="article-26659.s18">Review Questions</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26659" sec="article-26659.s19">References</SectionTitle></Section></Sections><ContributionDate><Year>2021</Year><Month>7</Month><Day>31</Day></ContributionDate><ReferenceList><Reference><Citation>Jung M, Bae JM, Jeon YK, Jung KC, Cho SW, Won JK. Parathyroid adenoma with prominent lymphocytic infiltrate having histological features highly suggestive of IgG4-related disease: a case report and literature review. Endocr J. 2019 Apr 25;66(4):379-385.</Citation><ArticleIdList><ArticleId IdType="pubmed">30726786</ArticleId></ArticleIdList></Reference><Reference><Citation>Buryakina SA, Tarbaeva NV, Volevodz NN, Dedov II, Kovalevich LD, Karmazanovskiy GG. Computed tomography diagnosis of primary hyperparathyroidism. Ter Arkh. 2018 Apr 19;90(4):60-66.</Citation><ArticleIdList><ArticleId IdType="pubmed">30701876</ArticleId></ArticleIdList></Reference><Reference><Citation>Cetani F, Saponaro F, Marcocci C. Non-surgical management of primary hyperparathyroidism. Best Pract Res Clin Endocrinol Metab. 2018 Dec;32(6):821-835.</Citation><ArticleIdList><ArticleId IdType="pubmed">30665549</ArticleId></ArticleIdList></Reference><Reference><Citation>Harach HR, Sánchez SS, Williams ED. Pathology of the autonomously functioning (hot) thyroid nodule. Ann Diagn Pathol. 2002 Feb;6(1):10-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11842375</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang H, Li M, Pan J, Tong W, Cheng M, Liang J, Zheng Y, Xie X. Ultrasound combined with biochemical parameters can be used to differentiate parathyroid carcinoma from benign tumors in patients with primary hyperparathyroidism. Clin Hemorheol Microcirc. 2020;76(3):351-359.</Citation><ArticleIdList><ArticleId IdType="pubmed">32675398</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigo JP, Hernandez-Prera JC, Randolph GW, Zafereo ME, Hartl DM, Silver CE, Suárez C, Owen RP, Bradford CR, Mäkitie AA, Shaha AR, Bishop JA, Rinaldo A, Ferlito A. Parathyroid cancer: An update. Cancer Treat Rev. 2020 Jun;86:102012.</Citation><ArticleIdList><ArticleId IdType="pubmed">32247225</ArticleId></ArticleIdList></Reference><Reference><Citation>Cinque L, Pugliese F, Salcuni AS, Scillitani A, Guarnieri V. Molecular pathogenesis of parathyroid tumours. Best Pract Res Clin Endocrinol Metab. 2018 Dec;32(6):891-908.</Citation><ArticleIdList><ArticleId IdType="pubmed">30477753</ArticleId></ArticleIdList></Reference><Reference><Citation>Gebauer J, Higham C, Langer T, Denzer C, Brabant G. Long-Term Endocrine and Metabolic Consequences of Cancer Treatment: A Systematic Review. Endocr Rev. 2019 Jun 01;40(3):711-767.</Citation><ArticleIdList><ArticleId IdType="pubmed">30476004</ArticleId></ArticleIdList></Reference><Reference><Citation>Quaglino F, Marchese V, Lemini R, Piovesan A, Mazza E, Viora T, Taraglio S. Parathyroid carcinoma. A single Institution experience and a review of the international literature. Ann Ital Chir. 2018;89:295-304.</Citation><ArticleIdList><ArticleId IdType="pubmed">30337508</ArticleId></ArticleIdList></Reference><Reference><Citation>Shane E. Clinical review 122: Parathyroid carcinoma. J Clin Endocrinol Metab. 2001 Feb;86(2):485-93.</Citation><ArticleIdList><ArticleId IdType="pubmed">11157996</ArticleId></ArticleIdList></Reference><Reference><Citation>Quaglino F, Marchese V, Lemini R, Piovesan A, Mazza E, Viora T, Taraglio S. Parathyroid carcinoma. A single Institution experience and a review of the international literature. Ann Ital Chir. 2018 Jun 11;7</Citation><ArticleIdList><ArticleId IdType="pubmed">30337503</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller HR, Record JL, Lall NU. Multiple Endocrine Neoplasia Type 1: A Case Report With Review of Imaging Findings. Ochsner J. 2018 Summer;18(2):170-175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6135292</ArticleId><ArticleId IdType="pubmed">30258300</ArticleId></ArticleIdList></Reference><Reference><Citation>Zagzag J, Hu MI, Fisher SB, Perrier ND. Hypercalcemia and cancer: Differential diagnosis and treatment. CA Cancer J Clin. 2018 Sep;68(5):377-386.</Citation><ArticleIdList><ArticleId IdType="pubmed">30240520</ArticleId></ArticleIdList></Reference><Reference><Citation>Nayyar SS, Thiagarajan S, Chaukar D, Laskar SG, Patil A, Mahajan A, Shah S. Parathyroid Carcinoma-An Experience of the Enigma Over 10 Years. Indian J Endocrinol Metab. 2020 Mar-Apr;24(2):137-142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7333759</ArticleId><ArticleId IdType="pubmed">32699779</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaapveld M, Jorna FH, Aben KK, Haak HR, Plukker JT, Links TP. Incidence and prognosis of parathyroid gland carcinoma: a population-based study in The Netherlands estimating the preoperative diagnosis. Am J Surg. 2011 Nov;202(5):590-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">21861982</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing Z, Qiu Y, Yang Q, Yu Y, Liu J, Fei Y, Su A, Zhu J. Thyroid cancer neck lymph nodes metastasis: Meta-analysis of US and CT diagnosis. Eur J Radiol. 2020 Aug;129:109103.</Citation><ArticleIdList><ArticleId IdType="pubmed">32574937</ArticleId></ArticleIdList></Reference><Reference><Citation>PDQ Adult Treatment Editorial Board. PDQ Cancer Information Summaries [Internet] National Cancer Institute (US); Bethesda (MD): 2020. Jul 22, Parathyroid Cancer Treatment (PDQ®): Health Professional Version.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Dood RL, Zhao Y, Armbruster SD, Coleman RL, Tworoger S, Sood AK, Baggerly KA. Defining Survivorship Trajectories Across Patients With Solid Tumors: An Evidence-Based Approach. JAMA Oncol. 2018 Nov 01;4(11):1519-1526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6248088</ArticleId><ArticleId IdType="pubmed">29860375</ArticleId></ArticleIdList></Reference></ReferenceList></BookDocument><PubmedBookData><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30085580</ArticleId></ArticleIdList></PubmedBookData></PubmedBookArticle></PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedBookArticle><BookDocument><PMID Version="1">30085580</PMID><ArticleIdList><ArticleId IdType="bookaccession">NBK519038</ArticleId></ArticleIdList><Book><Publisher><PublisherName>StatPearls Publishing</PublisherName><PublisherLocation>Treasure Island (FL)</PublisherLocation></Publisher><BookTitle book="statpearls">StatPearls</BookTitle><PubDate><Year>2022</Year><Month>01</Month></PubDate><BeginningDate><Year>2022</Year><Month>01</Month></BeginningDate><Medium>Internet</Medium></Book><ArticleTitle book="statpearls" part="article-26659">Parathyroid Cancer</ArticleTitle><Language>eng</Language><AuthorList Type="authors" CompleteYN="Y"><Author ValidYN="Y"><LastName>Byrd</LastName><ForeName>Colin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>McLaren Oakland</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kashyap</LastName><ForeName>Sarang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Easton Hospital</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwartowitz</LastName><ForeName>Gary</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>McLaren Oakland</Affiliation></AffiliationInfo></Author></AuthorList><PublicationType UI="D000072643">Study Guide</PublicationType><Abstract><AbstractText>Parathyroid carcinoma is a rare, malignant neoplasm originating from the parathyroid gland. The normal weight and size of the parathyroid glands vary. The average weight is about 60 mg. The average dimensions of each gland are 5 mm in length by 3 mm in width and 1 mm in thickness. The color of normal parathyroid glands is a yellow-brown color. There are generally 4 parathyroid glands, 2 superior and 2 inferior glands; they are located on the posterior and lateral surface of the thyroid gland. The location of the glands may vary based on the embryological descent during development. The inferior parathyroids and the thymus both develop from the third branchial pouch, whereas the parafollicular C cells and the superior parathyroids develop from the fourth branchial pouch. The superior parathyroid glands are frequently found near the cricothyroid junction, just superior to the intersection of the recurrent laryngeal nerve and the inferior thyroid artery. The superior parathyroids are closely associated with the posterior capsule of the superior thyroid pole. The inferior parathyroids have a more variable location, and greater than 50% are located at the inferior thyroid pole, but they can be located in the anterior mediastinum along the thyrothymic ligament. Rarely there is the presence of a supernumerary gland. The association of the parathyroid glands to the recurrent laryngeal nerve is an important anatomical relationship. The superior parathyroids are deep to the recurrent laryngeal nerve, and the inferior parathyroids are superficial. In most cases, each parathyroid gland's arterial supply is derived from the inferior thyroid artery, which is a branch of the thyrocervical trunk.  In 20% of cases, it may derive its blood supply from the superior thyroid artery, which is a branch from the external carotid artery. There is generally rich anastomosis between the parathyroids, larynx, pharynx, esophagus, and trachea. The venous drainage parallels the arterial vessels and drains into the internal jugular. The lymphatics of the parathyroid drain into the deep cervical and pretracheal lymph nodes, similar to the lymphatic drainage of the thyroid gland.  The major functional cells of the parathyroid are the chief cells, which contain many cytoplasmic secretory granules. These are responsible for producing parathyroid hormone. The second cell type that makes up the parathyroid parenchyma is the oxyphil cell. Their function is unknown, but they tend to be rich in mitochondria. Parathyroid glands with high concentrations of oxyphil cells may be more prone to hyperfunction.  As with all malignancy, parathyroid carcinoma is a result of the uncontrolled or unregulated growth of the parathyroid cells, and most parathyroid carcinomas are functional - meaning they secrete parathyroid hormone (PTH). Parathyroid carcinoma can occur in any of the parathyroids and does not appear to have a predilection for either the superior or inferior glands (or supernumerary glands), though the rarity of the disease precludes any definitive conclusions. The hallmark characteristic is a very high serum PTH level, often into the thousands, which is rare in benign hyperparathyroidism.</AbstractText><CopyrightInformation>Copyright © 2022, StatPearls Publishing LLC.</CopyrightInformation></Abstract><Sections><Section><SectionTitle book="statpearls" part="article-26659" sec="article-26659.s1">Continuing Education Activity</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26659" sec="article-26659.s2">Introduction</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26659" sec="article-26659.s3">Etiology</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26659" sec="article-26659.s4">Epidemiology</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26659" sec="article-26659.s5">Pathophysiology</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26659" sec="article-26659.s6">Histopathology</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26659" sec="article-26659.s7">History and Physical</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26659" sec="article-26659.s8">Evaluation</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26659" sec="article-26659.s9">Treatment / Management</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26659" sec="article-26659.s10">Differential Diagnosis</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26659" sec="article-26659.s11">Staging</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26659" sec="article-26659.s12">Prognosis</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26659" sec="article-26659.s13">Postoperative and Rehabilitation Care</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26659" sec="article-26659.s14">Consultations</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26659" sec="article-26659.s15">Deterrence and Patient Education</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26659" sec="article-26659.s16">Pearls and Other Issues</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26659" sec="article-26659.s17">Enhancing Healthcare Team Outcomes</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26659" sec="article-26659.s18">Review Questions</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-26659" sec="article-26659.s19">References</SectionTitle></Section></Sections><ContributionDate><Year>2021</Year><Month>7</Month><Day>31</Day></ContributionDate><ReferenceList><Reference><Citation>Jung M, Bae JM, Jeon YK, Jung KC, Cho SW, Won JK. Parathyroid adenoma with prominent lymphocytic infiltrate having histological features highly suggestive of IgG4-related disease: a case report and literature review. Endocr J. 2019 Apr 25;66(4):379-385.</Citation><ArticleIdList><ArticleId IdType="pubmed">30726786</ArticleId></ArticleIdList></Reference><Reference><Citation>Buryakina SA, Tarbaeva NV, Volevodz NN, Dedov II, Kovalevich LD, Karmazanovskiy GG. Computed tomography diagnosis of primary hyperparathyroidism. Ter Arkh. 2018 Apr 19;90(4):60-66.</Citation><ArticleIdList><ArticleId IdType="pubmed">30701876</ArticleId></ArticleIdList></Reference><Reference><Citation>Cetani F, Saponaro F, Marcocci C. Non-surgical management of primary hyperparathyroidism. Best Pract Res Clin Endocrinol Metab. 2018 Dec;32(6):821-835.</Citation><ArticleIdList><ArticleId IdType="pubmed">30665549</ArticleId></ArticleIdList></Reference><Reference><Citation>Harach HR, Sánchez SS, Williams ED. Pathology of the autonomously functioning (hot) thyroid nodule. Ann Diagn Pathol. 2002 Feb;6(1):10-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11842375</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang H, Li M, Pan J, Tong W, Cheng M, Liang J, Zheng Y, Xie X. Ultrasound combined with biochemical parameters can be used to differentiate parathyroid carcinoma from benign tumors in patients with primary hyperparathyroidism. Clin Hemorheol Microcirc. 2020;76(3):351-359.</Citation><ArticleIdList><ArticleId IdType="pubmed">32675398</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigo JP, Hernandez-Prera JC, Randolph GW, Zafereo ME, Hartl DM, Silver CE, Suárez C, Owen RP, Bradford CR, Mäkitie AA, Shaha AR, Bishop JA, Rinaldo A, Ferlito A. Parathyroid cancer: An update. Cancer Treat Rev. 2020 Jun;86:102012.</Citation><ArticleIdList><ArticleId IdType="pubmed">32247225</ArticleId></ArticleIdList></Reference><Reference><Citation>Cinque L, Pugliese F, Salcuni AS, Scillitani A, Guarnieri V. Molecular pathogenesis of parathyroid tumours. Best Pract Res Clin Endocrinol Metab. 2018 Dec;32(6):891-908.</Citation><ArticleIdList><ArticleId IdType="pubmed">30477753</ArticleId></ArticleIdList></Reference><Reference><Citation>Gebauer J, Higham C, Langer T, Denzer C, Brabant G. Long-Term Endocrine and Metabolic Consequences of Cancer Treatment: A Systematic Review. Endocr Rev. 2019 Jun 01;40(3):711-767.</Citation><ArticleIdList><ArticleId IdType="pubmed">30476004</ArticleId></ArticleIdList></Reference><Reference><Citation>Quaglino F, Marchese V, Lemini R, Piovesan A, Mazza E, Viora T, Taraglio S. Parathyroid carcinoma. A single Institution experience and a review of the international literature. Ann Ital Chir. 2018;89:295-304.</Citation><ArticleIdList><ArticleId IdType="pubmed">30337508</ArticleId></ArticleIdList></Reference><Reference><Citation>Shane E. Clinical review 122: Parathyroid carcinoma. J Clin Endocrinol Metab. 2001 Feb;86(2):485-93.</Citation><ArticleIdList><ArticleId IdType="pubmed">11157996</ArticleId></ArticleIdList></Reference><Reference><Citation>Quaglino F, Marchese V, Lemini R, Piovesan A, Mazza E, Viora T, Taraglio S. Parathyroid carcinoma. A single Institution experience and a review of the international literature. Ann Ital Chir. 2018 Jun 11;7</Citation><ArticleIdList><ArticleId IdType="pubmed">30337503</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller HR, Record JL, Lall NU. Multiple Endocrine Neoplasia Type 1: A Case Report With Review of Imaging Findings. Ochsner J. 2018 Summer;18(2):170-175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6135292</ArticleId><ArticleId IdType="pubmed">30258300</ArticleId></ArticleIdList></Reference><Reference><Citation>Zagzag J, Hu MI, Fisher SB, Perrier ND. Hypercalcemia and cancer: Differential diagnosis and treatment. CA Cancer J Clin. 2018 Sep;68(5):377-386.</Citation><ArticleIdList><ArticleId IdType="pubmed">30240520</ArticleId></ArticleIdList></Reference><Reference><Citation>Nayyar SS, Thiagarajan S, Chaukar D, Laskar SG, Patil A, Mahajan A, Shah S. Parathyroid Carcinoma-An Experience of the Enigma Over 10 Years. Indian J Endocrinol Metab. 2020 Mar-Apr;24(2):137-142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7333759</ArticleId><ArticleId IdType="pubmed">32699779</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaapveld M, Jorna FH, Aben KK, Haak HR, Plukker JT, Links TP. Incidence and prognosis of parathyroid gland carcinoma: a population-based study in The Netherlands estimating the preoperative diagnosis. Am J Surg. 2011 Nov;202(5):590-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">21861982</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing Z, Qiu Y, Yang Q, Yu Y, Liu J, Fei Y, Su A, Zhu J. Thyroid cancer neck lymph nodes metastasis: Meta-analysis of US and CT diagnosis. Eur J Radiol. 2020 Aug;129:109103.</Citation><ArticleIdList><ArticleId IdType="pubmed">32574937</ArticleId></ArticleIdList></Reference><Reference><Citation>PDQ Adult Treatment Editorial Board. PDQ Cancer Information Summaries [Internet] National Cancer Institute (US); Bethesda (MD): 2020. Jul 22, Parathyroid Cancer Treatment (PDQ®): Health Professional Version.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Dood RL, Zhao Y, Armbruster SD, Coleman RL, Tworoger S, Sood AK, Baggerly KA. Defining Survivorship Trajectories Across Patients With Solid Tumors: An Evidence-Based Approach. JAMA Oncol. 2018 Nov 01;4(11):1519-1526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6248088</ArticleId><ArticleId IdType="pubmed">29860375</ArticleId></ArticleIdList></Reference></ReferenceList></BookDocument><PubmedBookData><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30085580</ArticleId></ArticleIdList></PubmedBookData></PubmedBookArticle></PubmedArticleSet>
